Evidence map›Paper›PMID 37843119›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group.

Kimberly E Hanson, Ritu Banerjee, Sarah B Doernberg, Scott R Evans, Lauren Komarow, Michael J Satlin, Nyssa Schwager, Patricia J Simner, L Gayani Tillekeratne, Robin Patel and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Kimberly E HansonDivision of Infectious Diseases, Department of Medicine, University of Utah, Salt Lake City, Utah, USA.
Ritu BanerjeeDivision of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sarah B DoernbergDivision of Infectious Diseases, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Scott R EvansDepartment of Biostatistics, George Washington University, Washington, DC, USA.
Lauren KomarowGeorge Washington University Biostatistics Center, Rockville, Maryland, USA.
Michael J SatlinDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
Nyssa SchwagerDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Patricia J SimnerDivision of Medical Microbiology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
L Gayani TillekeratneDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Antibacterial Resistance Leadership Group
Duke University · USGeorge Washington University · USCornell University · USJohns Hopkins University · USMayo Clinic · USUniversity of California, San Francisco · USUniversity of Utah · USVanderbilt University Medical Center · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
NIAID NIH HHS UM1 AI104681NIH HHS UM1AI104681
6 · The paper itself

Abstract

The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections.

Indexed as

Gram-Negative Bacterial InfectionsLeadershipAnti-Bacterial AgentsDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaHumansMicrobial Sensitivity TestsAnti-Bacterial Agentsantibacterial resistancebacterial infectionsdiagnostics

Identifiers

PMID37843119
PMCPMC10578045
OpenAlexW4387661359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.